950 Winter Street
About Eloxx Pharmaceuticals
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.
YEAR FOUNDED: 2013
Chairman of the Board & CEO: Bob Ward
CMO: Dr. Pedro Huertas
CFO: Gregory Weaver
VP CMC: John van Duzer
Investor Relations: Barbara Ryan
VP Translational Science: Neal Sharpe
113 articles about Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. (“Eloxx”) (OTCQB: SVOND), a clinical-stage biopharmaceutical company developing novel small molecule medicines...
The Company will be known as Eloxx Pharmaceuticals following the completion of the transaction, and began trading on OTCQB Market under the new name effective as of December 20, 2017.
Eloxx today announced the two companies have completed their previously announced acquisition transaction effective as of December 19, 2017.
The trial is being run in Belgium, and data are expected at the end of the fourth quarter 2018.
Eloxx Pharmaceuticals Announces Expansion Of Intellectual Property Estate For ELX-02 With Newly Granted Patent In Europe
Sevion Therapeutics and Eloxx Pharmaceuticals announcedd that the European Patent Office (EPO) has granted a patent covering the Company's lead product candidate, ELX-02, as well as other proprietary compounds.
Eloxx Pharma Expands Management Team To Support Rapid Development Of Lead Drug Candidate ELX-02 For The Treatment Of Rare Genetic Diseases
Eloxx Pharma Secures US$8 Million Investment From LSP, Increasing Total Raised In Series C To US$38 Million
Eloxx Pharma Receives A US$6 Million Investment From KIP And DCS To Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
Eloxx Pharma Receives A US$5 Million Investment From Quark Venture And GF Securities To Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases
Eloxx Pharma Announces Orphan Drug Designation In The U.S. And Europe For ELX-02 In Mucopolysacchardisis Type 1 (MPS 1)